FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588725186> ?p ?o ?g. }

• W2588725186 abstract "Abstract Lipid encapsulation of chemotherapeutic agents facilitates local delivery of highly concentrated antineoplastics to tumors while ensuring an adequate duration of drug exposure and reducing systemic toxicity. Using novel technology, we have encapsulated nanoparticulate (100 nM) arsenic trioxide (ATO) at high density in “nanobins,” biocompatible lipids and polymers that undergo a change in permeability when exposed to intracellular conditions, releasing drug cargo into the acidic tumor microenvironment (J. Am. Chem. Soc.2006, 128: 13348-9). At low concentrations, ATO is an effective agent in the treatment of acute promyelocytic leukemia, causing differentiation and turnover of PML. At higher but potentially toxic concentrations, ATO induces programmed cell death through the generation of reactive oxygen species and its effects on other proapoptotic signaling pathways. A preliminary dose-range finding study was completed comparing the toxicity profiles of free ATO and nanobin formulations of arsenic based on loading procedures using either cobalt (Co) or nickel (Ni). Female Balb/c mice were injected intraperitoneally with either a single dose of free or nanobin formulations of ATO at 20, 40, 60, 100 or 200 μmol/kg of elemental As. Mice were assessed daily for the first 5 days after injection and then every second day thereafter for a total study duration of 14 days and monitored for body weight and clinical signs. The maximum tolerated doses for both the Co- and Ni-ATO formulations were approximately 100 – 200 μmol/kg as a single intraperitoneal injection. Efficacy experiments for the Ni-ATO-nanobins were conducted in a murine (RAG2-M) xenograft model in which the mantle cell lymphoma cell line Z138C was injected subcutaneously. On day 21, when the average tumor volume was 50–100 mg, weekly injections of saline, empty nanobins, or the Ni-ATO nanobins at 60 μmol/kg were begun. Cohorts of mice received either two or three weekly injections. Mice bearing tumors of 1000 mm3 or greater were sacrificed. Results were normalized to the tumor size at the time that treatment was initiated (day 21) and are represented as fold-increase in tumor measured with calipers three times weekly. The results of the three weekly injections are illustrated below. Following two injections, the curves began to separate showing a significant inhibition of tumor growth that persists for two weeks beyond the last injection (p &lt; 0.001). Two weekly injections also impacted tumor growth significantly (p &lt; 0.01; data not shown). These results provide rationale for further preclinical investigation of this novel therapeutic. Figure Figure" @default.
• W2588725186 created "2017-02-24" @default.
• W2588725186 creator A5003670546 @default.
• W2588725186 creator A5010130956 @default.
• W2588725186 creator A5033122071 @default.
• W2588725186 creator A5044540709 @default.
• W2588725186 creator A5050976890 @default.
• W2588725186 creator A5070792731 @default.
• W2588725186 creator A5079438223 @default.
• W2588725186 creator A5081257186 @default.
• W2588725186 date "2008-11-16" @default.
• W2588725186 modified "2023-09-27" @default.
• W2588725186 title "Triggered Release of Nanoparticulate Arsenic Trioxide for Treatment of Malignant Lymphomas: Preclinical Studies" @default.
• W2588725186 doi "https://doi.org/10.1182/blood.v112.11.4989.4989" @default.
• W2588725186 hasPublicationYear "2008" @default.
• W2588725186 type Work @default.
• W2588725186 sameAs 2588725186 @default.
• W2588725186 citedByCount "0" @default.
• W2588725186 crossrefType "journal-article" @default.
• W2588725186 hasAuthorship W2588725186A5003670546 @default.
• W2588725186 hasAuthorship W2588725186A5010130956 @default.
• W2588725186 hasAuthorship W2588725186A5033122071 @default.
• W2588725186 hasAuthorship W2588725186A5044540709 @default.
• W2588725186 hasAuthorship W2588725186A5050976890 @default.
• W2588725186 hasAuthorship W2588725186A5070792731 @default.
• W2588725186 hasAuthorship W2588725186A5079438223 @default.
• W2588725186 hasAuthorship W2588725186A5081257186 @default.
• W2588725186 hasConcept C104317684 @default.
• W2588725186 hasConcept C178790620 @default.
• W2588725186 hasConcept C185592680 @default.
• W2588725186 hasConcept C2776601000 @default.
• W2588725186 hasConcept C2780386689 @default.
• W2588725186 hasConcept C2781121885 @default.
• W2588725186 hasConcept C29730261 @default.
• W2588725186 hasConcept C502230775 @default.
• W2588725186 hasConcept C55493867 @default.
• W2588725186 hasConcept C71924100 @default.
• W2588725186 hasConcept C98274493 @default.
• W2588725186 hasConceptScore W2588725186C104317684 @default.
• W2588725186 hasConceptScore W2588725186C178790620 @default.
• W2588725186 hasConceptScore W2588725186C185592680 @default.
• W2588725186 hasConceptScore W2588725186C2776601000 @default.
• W2588725186 hasConceptScore W2588725186C2780386689 @default.
• W2588725186 hasConceptScore W2588725186C2781121885 @default.
• W2588725186 hasConceptScore W2588725186C29730261 @default.
• W2588725186 hasConceptScore W2588725186C502230775 @default.
• W2588725186 hasConceptScore W2588725186C55493867 @default.
• W2588725186 hasConceptScore W2588725186C71924100 @default.
• W2588725186 hasConceptScore W2588725186C98274493 @default.
• W2588725186 hasLocation W25887251861 @default.
• W2588725186 hasOpenAccess W2588725186 @default.
• W2588725186 hasPrimaryLocation W25887251861 @default.
• W2588725186 hasRelatedWork W1443108546 @default.
• W2588725186 hasRelatedWork W1545469100 @default.
• W2588725186 hasRelatedWork W1562693843 @default.
• W2588725186 hasRelatedWork W2240005626 @default.
• W2588725186 hasRelatedWork W2328569641 @default.
• W2588725186 hasRelatedWork W2348029488 @default.
• W2588725186 hasRelatedWork W2359170993 @default.
• W2588725186 hasRelatedWork W2366793750 @default.
• W2588725186 hasRelatedWork W2369183795 @default.
• W2588725186 hasRelatedWork W2378521571 @default.
• W2588725186 hasRelatedWork W2380807696 @default.
• W2588725186 hasRelatedWork W2385410762 @default.
• W2588725186 hasRelatedWork W2388762021 @default.
• W2588725186 hasRelatedWork W2398845841 @default.
• W2588725186 hasRelatedWork W2410286296 @default.
• W2588725186 hasRelatedWork W2545657964 @default.
• W2588725186 hasRelatedWork W2557733183 @default.
• W2588725186 hasRelatedWork W2784043644 @default.
• W2588725186 hasRelatedWork W2301479464 @default.
• W2588725186 hasRelatedWork W2506196785 @default.
• W2588725186 isParatext "false" @default.
• W2588725186 isRetracted "false" @default.
• W2588725186 magId "2588725186" @default.
• W2588725186 workType "article" @default.